4.0
Mar 3, 2025
Recommend
CEO approval
Business Outlook
Pros
Good exposure to pharma industry and clientele.
Cons
Still carrying a mentality of boutique consulting even though the firm is a size able consulting firm. Poor acquisitions in recent times hampering growth